Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
MWN-AI** Summary
Therma Bright Inc. (TSXV: THRM) has announced an expansion of its collaboration with Gen-X Med, a medical product distributor, following a successful initial transaction of 200 Venowave™ VW5 units aimed at specialized knee surgeons within the U.S. healthcare network. This development, disclosed on September 24, 2025, underscores Therma Bright's commitment to enhancing vascular compression therapy and improving patient outcomes, particularly in the lucrative market of specialized knee surgeries.
The Venowave™ VW5 is a portable, FDA-designated Durable Medical Equipment (DME) device that employs a unique wave-like motion to promote blood circulation and lymphatic function. Clinical studies have demonstrated a significant improvement in venous blood flow—64% after just two minutes and 88% after 50 minutes—making it a potent tool for post-surgical recovery. The device is currently the only mobile mechanical compression system in the U.S. eligible for Medicare reimbursement.
Beau Wood, President of Gen-X Med, remarked on the successful performance of the initial order and expressed optimism for future sales. Rob Fia, CEO of Therma Bright, echoed these sentiments, emphasizing the strategic nature of the partnership and its alignment with the company's mission to deliver innovative medical solutions.
The global compression therapy market, valued at $4.18 billion in 2024, is anticipated to grow to approximately $6.72 billion by 2033—an encouraging indicator for the prospects of the Venowave and its application in post-operative care.
As both companies move forward, they aim to enhance awareness and adoption of the Venowave™ VW5, contributing to better post-surgical outcomes and addressing key healthcare challenges in the U.S. market.
MWN-AI** Analysis
Therma Bright Inc. (TSXV: THRM) has entered an exciting phase of growth following its strategic partnership with Gen-X Med, especially following the successful initial sale of 200 Venowave™ VW5 units aimed at specialized knee surgeons in the U.S. This collaboration targets a high-value segment of the healthcare market, where the potential for further penetration is significant, particularly as the U.S. medical device market continues to expand.
The Venowave™ VW5, which has demonstrated clinical efficacy by enhancing venous blood flow significantly, offers substantial benefits for post-operative recovery, aligning well with the current healthcare focus on reducing complications and readmission rates. As the device is designated as Durable Medical Equipment (DME) and has already received Medicare approval, it stands apart in a competitive marketplace that is projected to grow exponentially, increasing from $4.18 billion in 2024 to an expected $6.72 billion by 2033.
Given the strategic alliances and robust clinical outcomes associated with the Venowave™, investors might find Therma Bright an appealing opportunity. The positive momentum from Gen-X Med’s endorsement and the anticipated increase in product orders could provide a solid revenue stream moving forward.
However, investors should heed the company's caution regarding forward-looking statements, noting risks inherent in the market. While the growth of the compression therapy field is supported by strong projections, potential challenges exist, such as market competition and regulatory fluctuations.
In conclusion, for investors considering entry into Therma Bright's stock, the ongoing partnership with Gen-X Med and the growth potential of the Venowave™ VW5 create a favorable investment case, but one should remain cognizant of the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure. Specialized knee surgeries represent a high value and growing segment of the U.S. healthcare market.
"We are pleased to partner with Therma Bright in offering the Venowave™ VW5 to our doctor network," shared Beau Wood, President, Gen-X Med. "We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution."
Rob Fia, CEO of Therma Bright, added, "This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave™ offers significant advantages for patients and the U.S. healthcare system by reducing post-surgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value."
According to a November 2024 press announcement from Straits Research, the global compression therapy market was valued at $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033, representing a compound annual growth rate (CAGR) of 7.30% from 2025 to 2033.
About the Venowave™ VW5
The Venowave™ VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated Durable Medical Equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by 64% after just two minutes of use and 88% after 50 minutes, the Venowave™ is the only Medicare-approved reimbursable mobile mechanical compression system available in the U.S. under its HCPCS code E0683. It provides a comfortable and simple treatment solution to accelerate post-operative recovery while managing pain and swelling.
About Gen-X Med
Gen-X Med is an Arlington, Texas-based distributor committed to providing healthcare professionals with specialized, vetted products and exceptional client care. The company's portfolio includes durable medical equipment (DME) products, with a focus on sourcing and providing the most qualified products and services to meet the needs of its clients.
Visit: http://www.genxmed.net/
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: (https://www.thermabright.com).
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on X:
https://x.com/Bright_Therma
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267679
FAQ**
How does the initial sale of 200 Venowave™ VW5 units to specialized knee surgeons position Therma Bright Inc. THRM:CC for future growth in the expanding U.S. healthcare market?
What specific strategies does Therma Bright Inc. THRM:CC plan to implement to enhance awareness and adoption of the Venowave™ VW5 among healthcare professionals and patients?
Could you elaborate on the anticipated benefits and outcomes documented from the initial sales of the Venowave™ VW5 units in terms of patient recovery and cost reduction for healthcare facilities?
How does the partnership with Gen-X Med align with Therma Bright Inc. THRM:CC's overall mission and goals within the competitive landscape of the medical device sector?
**MWN-AI FAQ is based on asking OpenAI questions about Therma Bright Inc. (TSXVC: THRM:CC).
NASDAQ: THRM:CC
THRM:CC Trading
-2.78% G/L:
$0.175 Last:
379,113 Volume:
$0.175 Open:
